197 related articles for article (PubMed ID: 1808464)
21. Protective activity of an intravenous immune globulin (human) enriched in antibody against lipopolysaccharide antigens of Pseudomonas aeruginosa.
Collins MS; Roby RE
Am J Med; 1984 Mar; 76(3A):168-74. PubMed ID: 6424446
[TBL] [Abstract][Full Text] [Related]
22. Oral immunization with bacterial polysaccharide and adjuvant enhances antigen-specific pulmonary secretory antibody response and resistance to pneumonia.
Abraham E; Robinson A
Vaccine; 1991 Oct; 9(10):757-64. PubMed ID: 1759494
[TBL] [Abstract][Full Text] [Related]
23. [Pseudomonas aeruginosa immunoglobulin in experimental pneumonia].
Pennington JE; Pier GB
Infection; 1987; 15 Suppl 2():S47-50. PubMed ID: 3112020
[TBL] [Abstract][Full Text] [Related]
24. [Pseudomonas aeruginosa immunoglobulin in experimental pneumonia].
Pennington JE; Pier GB
Infection; 1987; 15(1):56-9. PubMed ID: 3106230
[TBL] [Abstract][Full Text] [Related]
25. Nonopsonic antibodies in cystic fibrosis. Pseudomonas aeruginosa lipopolysaccharide-specific immunoglobulin G antibodies from infected patient sera inhibit neutrophil oxidative responses.
Eichler I; Joris L; Hsu YP; Van Wye J; Bram R; Moss R
J Clin Invest; 1989 Dec; 84(6):1794-804. PubMed ID: 2512330
[TBL] [Abstract][Full Text] [Related]
26. Vaccination promotes TH1-like inflammation and survival in chronic Pseudomonas aeruginosa pneumonia. A new prophylactic principle.
Johansen HK; Cryz SJ; Hougen HP; Moser C; Høiby N
Behring Inst Mitt; 1997 Feb; (98):269-73. PubMed ID: 9382750
[TBL] [Abstract][Full Text] [Related]
27. MEDI3902 Correlates of Protection against Severe Pseudomonas aeruginosa Pneumonia in a Rabbit Acute Pneumonia Model.
Le HN; Quetz JS; Tran VG; Le VTM; Aguiar-Alves F; Pinheiro MG; Cheng L; Yu L; Sellman BR; Stover CK; DiGiandomenico A; Diep BA
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29483116
[No Abstract] [Full Text] [Related]
28. Safety, pharmacokinetics, and functional activity of human anti-Pseudomonas aeruginosa monoclonal antibodies in septic and nonseptic patients.
Saravolatz LD; Markowitz N; Collins MS; Bogdanoff D; Pennington JE
J Infect Dis; 1991 Oct; 164(4):803-6. PubMed ID: 1910070
[TBL] [Abstract][Full Text] [Related]
29. Establishment of stable cell lines producing anti-Pseudomonas aeruginosa monoclonal antibodies and their protective effects for the infection in mice.
O'Oka H; Chonan E; Mizutani K; Fukuda T; Kuroiwa Y; Ono Y; Shigeta S
Microbiol Immunol; 1992; 36(12):1305-16. PubMed ID: 1287405
[TBL] [Abstract][Full Text] [Related]
30. Preclinical in vitro and in vivo characterization of the fully human monoclonal IgM antibody KBPA101 specific for Pseudomonas aeruginosa serotype IATS-O11.
Horn MP; Zuercher AW; Imboden MA; Rudolf MP; Lazar H; Wu H; Hoiby N; Fas SC; Lang AB
Antimicrob Agents Chemother; 2010 Jun; 54(6):2338-44. PubMed ID: 20308370
[TBL] [Abstract][Full Text] [Related]
31. X-linked immunodeficient mice as a model for testing the protective efficacy of monoclonal antibodies against Pseudomonas aeruginosa.
Zweerink HJ; Gammon MC; Hutchison CF; Jackson JJ; Pier GB; Puckett JM; Sewell TJ; Sigal NH
Infect Immun; 1988 May; 56(5):1209-14. PubMed ID: 3128480
[TBL] [Abstract][Full Text] [Related]
32. IV Immunoglobulin for Acute Lung Injury and Bacteremia in Pseudomonas aeruginosa Pneumonia.
Katoh H; Yasumoto H; Shimizu M; Hamaoka S; Kinoshita M; Akiyama K; Sawa T
Crit Care Med; 2016 Jan; 44(1):e12-24. PubMed ID: 26317571
[TBL] [Abstract][Full Text] [Related]
33. Protection against infection with Pseudomonas aeruginosa by passive transfer of monoclonal antibodies to lipopolysaccharides and outer membrane proteins.
Sawada S; Suzuki M; Kawamura T; Fujinaga S; Masuho Y; Tomibe K
J Infect Dis; 1984 Oct; 150(4):570-6. PubMed ID: 6436393
[TBL] [Abstract][Full Text] [Related]
34. Bivalent flagellin immunotherapy protects mice against Pseudomonas aeruginosa infections in both acute pneumonia and burn wound models.
Ahmadi H; Behrouz B; Irajian G; Amirmozafari N; Naghavi S
Biologicals; 2017 Mar; 46():29-37. PubMed ID: 28065582
[TBL] [Abstract][Full Text] [Related]
35. Specific and nonspecific imaging of localized Fisher immunotype 1 Pseudomonas aeruginosa infection with radiolabeled monoclonal antibody.
Rubin RH; Young LS; Hansen WP; Nedelman M; Wilkinson R; Nelles MJ; Callahan R; Khaw BA; Strauss HW
J Nucl Med; 1988 May; 29(5):651-6. PubMed ID: 3131499
[TBL] [Abstract][Full Text] [Related]
36. Protective effects of intravenous immunoglobulin and antimicrobial agents on acute pneumonia in leukopenic mice.
Shimizu M; Katoh H; Hamaoka S; Kinoshita M; Akiyama K; Naito Y; Sawa T
J Infect Chemother; 2016 Apr; 22(4):240-7. PubMed ID: 26867796
[TBL] [Abstract][Full Text] [Related]
37. Specificity and function of murine monoclonal antibodies and immunization-induced human polyclonal antibodies to lipopolysaccharide subtypes of Pseudomonas aeruginosa serogroup 06.
Pier GB; Koles NL; Meluleni G; Hatano K; Pollack M
Infect Immun; 1994 Apr; 62(4):1137-43. PubMed ID: 8132318
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of antibodies against the N-terminal of Pseudomonas aeruginosa flagellin for treating infections in a murine burn wound model.
Barnea Y; Carmeli Y; Gur E; Kuzmenko B; Gat A; Neville LF; Eren R; Dagan S; Navon-Venezia S
Plast Reconstr Surg; 2006 Jun; 117(7):2284-91. PubMed ID: 16772930
[TBL] [Abstract][Full Text] [Related]
39. Functional properties of isotype-switched immunoglobulin M (IgM) and IgG monoclonal antibodies to Pseudomonas aeruginosa lipopolysaccharide.
Pollack M; Koles NL; Preston MJ; Brown BJ; Pier GB
Infect Immun; 1995 Nov; 63(11):4481-8. PubMed ID: 7591089
[TBL] [Abstract][Full Text] [Related]
40. A protective human monoclonal antibody directed to the outer core region of Pseudomonas aeruginosa lipopolysaccharide.
Terashima M; Uezumi I; Tomio T; Kato M; Irie K; Okuda T; Yokota S; Noguchi H
Infect Immun; 1991 Jan; 59(1):1-6. PubMed ID: 1898896
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
